Skip to main
ABRI
Privately held company

Abridge

$188.82

Source: Nasdaq Private Markets
$3.71 (2.00%)past six months

Abridge Valuation

Follow estimated valuations, share price trends, and company updates for Abridge.

Get updates

About Abridge

Abridge uses artificial intelligence to listen to and interpret spoken medical conversations and automatically turn them into organized clinical documentation that supports healthcare workflows and reduces administrative burden. Its technology focuses on enhancing clarity and efficiency in capturing key information from discussions between patients and clinicians, helping streamline record‑keeping...read more
Co-FounderShivdev Rao
Co-FounderZack Lipton
CEOShivdev Rao
COOJulia Chou
CFOSagar Sanghvi
CTOZack Lipton
HeadquartersPittsburgh, PA
Founded2018
SectorAI & Machine Learning

Abridge Funding History

Financing RoundDateAmount
Series EJun 24, 2025$300M
Abridge AI Series EMay 30, 2025Undisclosed
Series DFeb 17, 2025$250M
Series CFeb 22, 2024$141M
Series BOct 26, 2023$30M
Series A-1Aug 11, 2022$12M

Abridge lead investors

  • American College of Cardiology
  • Andreessen Horowitz
  • Aneesh Chopra
  • Bessemer Venture Partners
  • California Health Care Foundation
  • CapitalG
  • CVS Health
  • Elad Gil
  • Esther Dyson
  • Individuals
  • Institutional Venture Partners
  • Kaiser Permanente Ventures
  • KdT Ventures
  • Khosla Ventures
  • K. Ventures
  • Lifepoint Health
  • Lightspeed Venture Partners
  • Mass General Brigham (Artificial Intelligence and Digital Innovation Fund)
  • Mayo Clinic
  • NVentures
  • Pillar Companies
  • Redpoint Ventures
  • SCAN Group
  • Spark Capital
  • SV Angel
  • UC Investments (UCOP)
  • Union Square Ventures
  • UPMC Enterprises
  • Whistler Capital Partners
  • Wittington Ventures
  • Yoshua Bengio

FAQ

Frequently asked questions

Abridge's estimated secondary market share price is $188.82 as of April 2026.

Abridge's last official round, Series E, was for $300M.

Abridge's last known funding was on Jun 24, 2025 for $300M.

Abridge's major investors are American College of Cardiology, Andreessen Horowitz, Aneesh Chopra, Bessemer Venture Partners, California Health Care Foundation, CapitalG, CVS Health, Elad Gil, Esther Dyson, Individuals, Institutional Venture Partners, Kaiser Permanente Ventures, KdT Ventures, Khosla Ventures, K. Ventures, Lifepoint Health, Lightspeed Venture Partners, Mass General Brigham (Artificial Intelligence and Digital Innovation Fund), Mayo Clinic, NVentures, Pillar Companies, Redpoint Ventures, SCAN Group, Spark Capital, SV Angel, UC Investments (UCOP), Union Square Ventures, UPMC Enterprises, Whistler Capital Partners, Wittington Ventures, Yoshua Bengio.

As of May 31, 2026, Abridge is not yet publicly traded.

Abridge Valuation

Follow estimated valuations, share price trends, and company updates for Abridge.

Get updates